PF-Atlas › Clinical Trials › NCT03447249
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation
VX-659/TEZ/IVA · Phase 3
Registry ID
NCT03447249
Phase
Phase 3
Status
Completed
Drug / intervention
VX-659/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2018-03-07
Enrollment
385
Locations
101
About this trial
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03447249 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.